Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2023-08-14 Regulatory Filings
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02, which relates to the "Results of Operations and Financial Condition," and states that a press release announcing second quarter 2023 results is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length of the document is 3708 characters, which is relatively short and consistent with a current report filing. Given that this is a current report announcing earnings results but not the earnings release itself, the best classification is Regulatory Filings (RNS), as it is a regulatory announcement of a press release rather than the earnings release document itself.
2023-08-14 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-14 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter from a legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-1 filed by Zura Bio Limited. It discusses revisions to the registration statement, including details about securities being registered, disclosures about warrants, liquidity impact, and risk factors. The document is not the registration statement itself but a correspondence related to the SEC review process. It does not contain financial statements or detailed financial data but is a regulatory communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2023-08-11 English
S-1/A
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 2 to Form S-1 Registration Statement filed with the SEC, dated August 11, 2023. It is a registration statement under the Securities Act of 1933 for Zura Bio Limited. The text includes detailed information about securities being registered for resale by selling securityholders, descriptions of warrants, private placements, and business combination agreements. The document is a regulatory filing related to securities registration and offering, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement amendment. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-08-11 English
Regulatory Filings 2023
Regulatory Filings
2023-07-28 English
FORM 8-K
Investor Presentation Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 27, 2023, by Zura Bio Limited. It specifically references an attached Investor Presentation (Exhibit 99.1) and states that the presentation is being used for investor and analyst communications. The text explicitly calls the attached document an 'Investor Presentation' and describes its intended use. There is no substantive financial data or detailed report content within this filing itself; rather, it is a current report announcing the furnishing of an investor presentation. According to the classification rules, such a document is best classified as an Investor Presentation (IP).
2023-07-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.